NCT03420092 - A Study to Assess the Bioavailability of Different Formulations of AZD5718 and the Food Effect on the Selected Formulation of AZD5718 in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 5, 2018

Primary Completion Date

April 18, 2018

Study Completion Date

April 18, 2018

Conditions

Coronary Artery Disease

Interventions

DRUG

Form 1 of AZD5718 tablets

The participants will be dosed with Form 1 of AZD5718 following an overnight fast of at least 10 hours.

DRUG

Form 2 of AZD5718 tablets

The participants will be dosed with Form 2 of AZD5718 following an overnight fast of at least 10 hours.

DRUG

Form 3 of AZD5718 tablets

The participants will be dosed with Form 3 of AZD5718 following an overnight fast of at least 10 hours.

DRUG

Form 4 of AZD5718 tablets

The participants will be dosed with Form 4 of AZD5718 following an overnight fast of at least 10 hours.

DRUG

Form 5 of AZD5718 tablets

The participants will be dosed with Form 5 of AZD5718 following an overnight fast of at least 10 hours.

DRUG

Selected form (Form 2 - 5) of AZD5718 tablets

The participant will be administered with selected form (one of Form 2-5) of AZD5718 tablets 30 minutes after start of the meal.

Trial Locations (1)

Research Site, London